Serum neopterin as a prognostic indicator in patients with breast carcinoma

• Autorzy: Belma Kocer , Umit Turan , Suleyman Surmeli , Buket Altun , Sabahat Aksaray , Osman Yilmaz , Omer Cengiz
• Języki publikacji: EN

Abstrakty

EN

Neopterin is a useful indicator of the activation state of the cellular immune system, and an elevated level predicts prognosis in different types of tumors. The aim of this study was to evaluate serum neopterin levels if it is viable predictor for prognosis in breast carcinoma patients. Serum neopterin was investigated in 56 breast carcinoma patients, 16 patients with benign breast lesions and 16 healthy women as controls. Neopterin was measured by ELISA (Enzyme-linked immunosorbent assay). The clinicopathological parameters were determined by reviewing both medical charts and pathological records. All patients had been followed-up until September 2009 or death.The mean serum neopterin concentrations were 8.5 ± 5.2 nmol/L in patients with breast carcinoma, 6.5±3.1 nmol/L in patients with benign breast lesion and 8.1 ± 1.9 nmol/L in healthy volunteers (p>0.05). Elevated neopterin levels were significantly correlated with age, elevated serum CRP level, advanced stage and presence of the distant metastases (p<0.05). Overall survival was significantly shorter in patients with a serum neopterin level >10 nmol/L than patients with neopterin <10 nmol/L level (56 months vs. 76 months, p=0.011). Increased preoperative serum neopterin concentrations are associated with a poor prognosis in patients with breast carcinoma.

Słowa kluczowe

EN

Neopterin; ELISA; Breast carcinoma; Prognosis

• Czasopismo: Open Medicine
• Rocznik: 2010
• Tom: 5
• Numer: 5
• Strony: 544-550

Daty

wydano

2010-10-01

online

2010-08-20

Twórcy

autor

Belma Kocer

• 2nd General Surgery Clinics, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey,

autor

Umit Turan

• 2nd General Surgery Clinics, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

autor

Suleyman Surmeli

• 2nd General Surgery Clinics, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

autor

Buket Altun

• 2nd General Surgery Clinics, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

autor

Sabahat Aksaray

• Department of Microbiology, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

autor

Osman Yilmaz

• 2nd General Surgery Clinics, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

autor

Omer Cengiz

• 2nd General Surgery Clinics, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

Bibliografia

• [1] Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993; 101: 1–6 http://dx.doi.org/10.1159/000236491[Crossref]
• [2] Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81–141 http://dx.doi.org/10.1016/S0065-2423(08)60182-1[Crossref]
• [3] Fuchs D, et al. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988; 9: 150–5 http://dx.doi.org/10.1016/0167-5699(88)91203-0[Crossref]
• [4] Denz H, Griinewatd K, Thaler J, Huber H, Fuchs D, Hausen A, Reibnegger G, Werner ER, Wachter H. Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines 1989; 1: 167–170
• [5] Melichar B, Solichová D, Melicharová K, Malírová E, Cermanová M, Zadák Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006; 21: 190–198 [PubMed]
• [6] Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Letters 2009; June 3 [WoS]
• [7] Murr C, Bergant A, Widschwndter M, Heim K, Schrocksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clinical Chemistry 1999, 45; 11: 1998–2004 [PubMed]
• [8] Frick J, Aulitzky W, Fuchs D, Hausen H, Joos H, Reibnegger G, et al. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract. Urol Int 1985; 40: 155–9 http://dx.doi.org/10.1159/000281071[Crossref]
• [9] Melichar B, Solichova D, Svobodova I, Urbanek L, Melicharova K. Urinary Neopterin in Patients with upper Gastrointestinal, Biliary and Pancreatic Carcinomas. Pteridines 2006: 17; 20–24
• [10] World Health Organization. Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002. Available online at: http://www.who.int/whr/2004/annex/topic/en/annex-2-en.pdf. 2009; January 12
• [11] Yildirim Y, Gunel N, Coskun U, Pasaoglu H, Aslan S, Cetin A. Serum neopterin levels in patients with breast cancer. Med Oncol 2008; 25: 403–407 http://dx.doi.org/10.1007/s12032-008-9054-2[Crossref]
• [12] Berdowska A and Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J of Clinical Pharmacy and Therapeutics 2001; 26: 319–329 http://dx.doi.org/10.1046/j.1365-2710.2001.00358.x[Crossref]
• [13] Honlinger M, Fuchs D, Hausen A, Reibnegger, G, Schonitzer D, Werner ER, et al. [Serum neopterin determination for the additional safeguarding of blood transfusions. Our experiences with 76,587 blood donors]. Dtsch Med Wochenschr 1989;114:172–6 http://dx.doi.org/10.1055/s-2008-1066571[Crossref]
• [14] Melichar B, Solichova D, Freedmans RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006; 16: 240–252 http://dx.doi.org/10.1111/j.1525-1438.2006.00294.x[Crossref]
• [15] Hausen A, Bichlker A, Fuchs D, Hetzel H, Reibnegger G, Wachter H. Neopterin, a biochemical indicator of cellular immune reaction, in the detection and control of patients with neoplastic diseases. Cancer Detect Prev 1985; 8: 121–8
• [16] Bayram M, Bayram O, Boyunaga H, Guler Ozer. A research on the level of urine neopterin to see if it may provide a vital clue for a provisional diagnosis of breast cancer in menopausal women. Maturitas 2009; 48: 432–437 http://dx.doi.org/10.1016/j.maturitas.2003.11.006[Crossref]
• [17] Girgin G, Sahin T, Fuchs D, Kasuya H, Yuksek O, Tekin E, Baydar T. Immune system modulation in patients with malignant and benign breast disorders: tryptophan degradation and serum neopterin. Int J Biol Markers 2009; 11: none (Epub ahead of print)
• [18] Hoffmann G, Wirleitner B, Fichs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003; 52: 313–321 http://dx.doi.org/10.1007/s00011-003-1181-9[Crossref]
• [19] Melicharova K, Kalabova H, Kromova L, Urbanek L, Solichova D, Melichar B. Effect of comorbidity on urinary in patients with breast carcinoma. Eur J Cancer Care (Engl) 2009;13 (Epub ahead of print) [WoS]
• [20] Yoshida N, Ikemoto S, Narita K et al. Serum neopterin levels in renal cell carcinoma. Pteridines 2000; 11: 133–136
• [21] Schuler M, Peschel C, Schneller F et al. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J. Interferon Cytokine Res 1996; 16: 903–910 http://dx.doi.org/10.1089/jir.1996.16.903[Crossref]
• [22] Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res. 1999;19(3A):1721–8
• [23] Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett. 1993; 19: 89–92 http://dx.doi.org/10.1016/0014-5793(93)80627-7[Crossref]
• [24] Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Fuchs D. Neopterin derivatives modulate the nitration of tyrosine by peroxynitrite. Biochem Biophys Res Commun. 1998 Jul 20;248(2): 341–6 http://dx.doi.org/10.1006/bbrc.1998.8856[Crossref]
• [25] Weinberg F, Chandel NS. Reactive oxygen speciesdependent signalling regulates cancer. Cellular and Molecular Life Science 2009; Dec;66(23):3663–73. Epub 2009 Jul 24. Review http://dx.doi.org/10.1007/s00018-009-0099-y[Crossref]
• [26] Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D. Neopterin as a prognostic parameter in patients with squamous-cell carcinomas of the oral cavity. Int J Cancer 1998; 79: 476–480 http://dx.doi.org/10.1002/(SICI)1097-0215(19981023)79:5<476::AID-IJC5>3.0.CO;2-Y[Crossref]
• [27] Djordjevic VB, Stojanovic I, Cosic V, Zvezdanovic L, Deljanin-Ilic M, Dimic S, Kundalic B, Cvetkovic T, Jevtovic-Stoimenov T. Serum neopterin, nitric oxide, inducible nitric oxide synthase and tumor necrosis factor-α levels in patients with ischemic heart disease. Clin Chem Lab Med 2008; 46: 1149–1155 http://dx.doi.org/10.1515/CCLM.2008.213[WoS][Crossref]
• [28] Schobersberger W, Hoffman G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth musclecells. FEBS Lett 1995; 377: 461–4 http://dx.doi.org/10.1016/0014-5793(95)01393-8[Crossref]
• [29] Moncada S, Higgs A. The L-arginine -nitric oxide pathway. N Engl J Med 1993; 329: 2002–12 http://dx.doi.org/10.1056/NEJM199312303292706[Crossref]
• [30] Knowles RG, Moncada S. Nitric oxide sythases in mammals. Biochem J 1994; 298–58
• [31] Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K. Nitric oxide in breast cancer: Induction of vascular entothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006; 12: 1201–1207 http://dx.doi.org/10.1158/1078-0432.CCR-05-1269[Crossref]
• [32] Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC. p53 and vascular endothelial growth factor regulate tumor growth on NOS2-expression human carcinoma cells. Nat Med 1998; 4: 1371–6 http://dx.doi.org/10.1038/3957[Crossref]

Identyfikatory

DOI

10.2478/s11536-010-0017-6